Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael(Beth Israel Deaconess Medical Center), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Fernando Velayos(Kaiser Permanente San Francisco Medical Center), Shane Devlin, Gilaad G. Kaplan(University of Calgary), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Thomas Ullman(Montefiore Medical Center), Niels Vande Casteele(University of California San Diego), Patricia Kozuch(Thomas Jefferson University), Gil Melmed, Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Brian Bressler(University of British Columbia), Jennifer Jones(Dalhousie University), Miles Sparrow(Alfred Health), Leonard Baidoo(University of Pittsburgh Medical Center), Laura E. Raffals(Mayo Clinic)
Cited by 336
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k